Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.86 USD | 0.00% | -11.43% | -36.95% |
May. 09 | BioXcel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 09 | Transcript : BioXcel Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 |
Evolution of the average Target Price on BioXcel Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering BioXcel Therapeutics, Inc.
Canaccord Genuity | |
UBS | |
Truist Securities | |
HC Wainwright | |
Goldman Sachs | |
Mizuho Securities | |
Guggenheim | |
Jefferies & Co. | |
Berenberg Bank | |
BofA Securities |
EPS Revisions
- Stock Market
- Equities
- BTAI Stock
- Consensus BioXcel Therapeutics, Inc.